Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q4 2018 (← Previous) (Next →)

Filing Date: Jan 22, 2019

Total Value: $202B (100.0% shares, 0.0% debt)

Holdings (10)

CRSP CRISPR Therapeutics AG 51.0%

Value $103.1B Shares 3,608,874 Est. Cost $41.27 Unrealized -15.8%

VCYT Veracyte, Inc. 22.5%

Value $45.49B Shares 3,616,221 Est. Cost $11.03 Unrealized +7.2%

— Audentes Therapeutics, Inc. 12.7%

Value $25.68B Shares 1,204,615 Est. Cost $17810.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 4.4%

Value $8.817B Shares 2,215,384 Est. Cost $20.09 Unrealized -72.6%

— CymaBay Therapeutics, Inc. 4.2%

Value $8.537B Shares 1,084,696 Est. Cost $9871.60 Unrealized —

— Second Sight Medical Products, Inc. 2.0%

Value $3.979B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— ImmuneDesign Corp. 1.4%

Value $2.871B Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Clovis Oncology, Inc. 0.9%

Value $1.829B Shares 101,855 Est. Cost $56000.00 Unrealized —

— Achaogen, Inc. 0.8%

Value $1.576B Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— OpGen, Inc. 0.1%

Value $133M Shares 102,167 Est. Cost $1780.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	3,608,874	$103.1B	51.0%	$41.27	-15.8%	Common Stock	H17182108
VCYT	Veracyte, Inc.	3,616,221	$45.49B	22.5%	$11.03	+7.2%	Common Stock	92337F107
—	Audentes Therapeutics, Inc.	1,204,615	$25.68B	12.7%	$17810.00	—	Common Stock	05070R104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$8.817B	4.4%	$20.09	-72.6%	Common Stock	67576A100
—	CymaBay Therapeutics, Inc.	1,084,696	$8.537B	4.2%	$9871.60	—	Common Stock	23257D103
—	Second Sight Medical Products, Inc.	4,492,975	$3.979B	2.0%	$1210.00	—	Common Stock	81362J100
—	ImmuneDesign Corp.	2,208,210	$2.871B	1.4%	$7580.00	—	Common Stock	45252L103
—	Clovis Oncology, Inc.	101,855	$1.829B	0.9%	$56000.00	—	Common Stock	189464100
—	Achaogen, Inc.	1,281,152	$1.576B	0.8%	$13050.00	—	Common Stock	004449104
—	OpGen, Inc.	102,167	$133M	0.1%	$1780.00	—	Common Stock	68373L109